Table 1.
AML-CCLG2015 Regime.
| Regime | Drugs | Days | Injection methods | Dose (per day) | |
|---|---|---|---|---|---|
| Induction therapy | DAE/DAH Course I |
DNR | 1, 3, 5 | IV | 40 mg/m2 |
| Ara-C | 1 to 7 | IV | 200 mg/m2 | ||
| HHT (H group) | 1 to 5 | IV | 3 mg/m2 | ||
| VP-16 (E group) | 1 to 5 | IV | 100 mg/m2 | ||
| IAE/IAH Course II |
IDA | 1, 3, 5 | IV | 10 mg/m2 | |
| Ara-C | 1 to 7 | IV | 200 mg/m2 | ||
| HHT (H group) | 1 to 5 | IV | 3 mg/m2 | ||
| VP-16 (E group) | 1 to 5 | IV | 100 mg/m2 | ||
| Consolidation therapy | MA Course III |
Mitozantrone | 1, 2 | IV | 10 mg/m2 |
| Ara-C | 1 to 3 | IV | 4 g/m2 | ||
| HA Course IV |
HHT | 1 to 7 | IV | 3 mg/m2 | |
| Ara-C | 1 to 3 | IV | 2 g/m2 | ||
| CLASP Course V |
L-ASP | 2 | IM | 6000 U/m2 | |
| Ara-C (SR) | 1,2 | IV | 6 g/m2 | ||
| Ara-C (MR, HR) | 1 to 3 | IV | 6 g/m2 | ||
A(Ara-C): cytarabine; AML: acute myeloid leukemia; CCLG: Chinese Children’s Leukemia Group; D(DNR): daunorubicin; E(VP-16): etoposide; H(HHT): homoharringtonine; HR: high risk; I(IDA): idarubicin; IR: medium risk; IV: intravenous injection; L-ASP: L-asparaginasum; M: mitozantrone; SR: standard risk; DAE: DNR+Ara-C+VP-16; DAH: DNR+Ara-C+HHT; IAE: IDA+Ara-C+VP-16; IAH: IDA+Ara-C+HHT; MA: Mitozantrone+Ara-C; HA: HHT+Ara-C; CLASP: Ara-C+L-ASP.